Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group-Reference-Cited by-同舟云学术

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group

Published:2016-01 Issue: Volume:52 Page:173-180
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Patrikidou Anna,Domont Julien,Chabaud Sylvie,Ray-Coquard Isabelle,Coindre Jean-Michel,Bui-Nguyen Binh,Adenis Antoine,Rios Maria,Bertucci François,Duffaud Florence,Chevreau Christine,Cupissol Didier,Pérol David,Emile Jean-François,Blay Jean-Yves,Le Cesne Axel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial;Verweij;Lancet,2004

2. Phase III randomised, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033;Blanke;J Clin Oncol,2008

3. Long-term results from a randomised phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT;Blanke;J Clin Oncol,2008

4. Prospective multicentric randomised phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group;Blay;J Clin Oncol,2007

5. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial;Le Cesne;Lancet Oncol,2010

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma;Gynecologic Oncology;2024-09

2. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

3. Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research;Global Medical Genetics;2024-08-22

4. Pathological Complete Response After Neoadjuvant Imatinib in a Recurrent Duodenal Gastrointestinal Stromal Tumor (GIST);Cureus;2024-07-16

5. Survival outcomes and prognostic factors of advanced gastrointestinal stromal tumors: in the era of multiple tyrosine kinase inhibitors;Journal of Gastrointestinal Oncology;2024-06